Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report.

Jebsen NL, Apelseth TO, Haugland HK, Rekdal Ø, Patel H, Gjertsen BT, Jøssang DE

Journal of medical case reports10 Jun 2019Cited by 14 (Europe PMC)

PMID31177991PMCIDPMC6556957DOI10.1186/s13256-019-2088-6PepBankPUB-31177991

Summary

BackgroundDesmoid tumors are intermediary malignant, fibrous lesions occurring in various soft tissues. Surgical treatment is relentlessly challenging because of the propensity for local aggressive behavior and high risk of recurrence. Consequently, a wide range of oncological drugs and radiation therapy are being used; however, outcomes are unpredictable. We investigated whether local treatment with an oncolytic peptide could be beneficial in a patient with an unresectable desmoid tumor.Case presentationIn a young 29-year-old Caucasian woman who was diagnosed with a retromammary desmoid tumor infiltrating deeply into the anterior thoracic wall, surgery was considered excessively mutilating, and observation was recommended. The lesion progressed, however, and caused debilitating pain, despite nonsteroidal anti-inflammatory medication. Subcutaneous injections of human interferon-α (Multiferon®) resulted in reduced growth kinetics but had to be terminated because of development of symptomatic pneumonitis. Frequently used oncological treatment was withheld because of the toxicity profile, and the patient was instead included in a phase I study investigating transdermal intratumoral injection of LTX-315, an oncolytic peptide that induces anticancer immune responses ( ClinicalTrials.gov , NCT01986426 ). A marked increase of CD8⁺ tumor-infiltrating T cells in the lesion was complemented by upregulation of immune gene signature (including effector T-cell, T-helper type 1 cell, chemokine, and cytokine genes). These changes were followed by gradual symptom relief and long-term disease stabilization, indicating clinical benefit. LTX-315 was well tolerated until termination in week 16 after a serious allergic reaction.ConclusionsOur patient was treated with repeated intratumoral injections of LTX-315, resulting in tumor regression accompanied by upregulation of immune genes and T-cell infiltration. Local application of immunotherapy, minimizing systemic side effects, represents a novel treatment modality in desmoid tumors that should be tested in further clinical trials.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanCase report or seriesMechanism
In a woman with a desmoid tumor, LTX‑315 treatment increased tumor-infiltrating CD8+ T cells.
In plain wordsIn a woman with a desmoid tumor, LTX‑315 treatment increased CD8+ immune cells in the tumor.
Peptide
LTX-315
Outcome
IncreaseCD8+ T-cell infiltration
Study
n = 1
Outcome group
Immune response · Cancer
Studied dose
Dose not stated · transdermal intratumoral injectionAs given in this study (human).
Source sentences
Summary
A marked increase of CD8⁺ tumor-infiltrating T cells in the lesion was complemented by upregulation of immune gene signature (including effector T-cell, T-helper type 1 cell, chemokine, and cytokine genes).
2 context sentences(design, population, supporting numbers)
Summary · context
In a young 29-year-old Caucasian woman who was diagnosed with a retromammary desmoid tumor infiltrating deeply into the anterior thoracic wall, surgery was considered excessively mutilating, and observation was recommended.
Summary · context
the patient was instead included in a phase I study investigating transdermal intratumoral injection of LTX-315, an oncolytic peptide that induces anticancer immune responses
Show in the study text Report a problemFND-3117799101
02HumanCase report or seriesMechanism
In a woman with a desmoid tumor, LTX‑315 treatment increased the immune gene signature.
In plain wordsIn a woman with a desmoid tumor, LTX‑315 treatment increased immune gene activity.
Peptide
LTX-315
Outcome
IncreaseImmune gene signature
Study
n = 1
Outcome group
Immune response · Cancer
Studied dose
Dose not stated · transdermal intratumoral injectionAs given in this study (human).
Source sentences
Summary
A marked increase of CD8⁺ tumor-infiltrating T cells in the lesion was complemented by upregulation of immune gene signature (including effector T-cell, T-helper type 1 cell, chemokine, and cytokine genes).
2 context sentences(design, population, supporting numbers)
Summary · context
In a young 29-year-old Caucasian woman who was diagnosed with a retromammary desmoid tumor infiltrating deeply into the anterior thoracic wall, surgery was considered excessively mutilating, and observation was recommended.
Summary · context
the patient was instead included in a phase I study investigating transdermal intratumoral injection of LTX-315, an oncolytic peptide that induces anticancer immune responses
Show in the study text Report a problemFND-3117799102
03HumanCase report or seriesEfficacy outcome
In a woman with a desmoid tumor, immune changes after LTX‑315 treatment were followed by gradual symptom relief.
In plain wordsIn a woman with a desmoid tumor, symptoms gradually improved after LTX‑315 treatment.
Peptide
LTX-315
Outcome
DecreaseSymptom relief
Study
n = 1
Outcome group
Pain · Cancer
Studied dose
Dose not stated · transdermal intratumoral injectionAs given in this study (human).
Source sentences
Summary
These changes were followed by gradual symptom relief and long-term disease stabilization, indicating clinical benefit.
2 context sentences(design, population, supporting numbers)
Summary · context
In a young 29-year-old Caucasian woman who was diagnosed with a retromammary desmoid tumor infiltrating deeply into the anterior thoracic wall, surgery was considered excessively mutilating, and observation was recommended.
Summary · context
the patient was instead included in a phase I study investigating transdermal intratumoral injection of LTX-315, an oncolytic peptide that induces anticancer immune responses
Show in the study text Report a problemFND-3117799103
04HumanCase report or seriesEfficacy outcome
In a woman with a desmoid tumor, LTX‑315 treatment was followed by long-term disease stabilization.
In plain wordsIn a woman with a desmoid tumor, disease remained stable long term after LTX‑315 treatment.
Peptide
LTX-315
Outcome
Not applicableDisease stabilization
Study
n = 1
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · transdermal intratumoral injectionAs given in this study (human).
Source sentences
Summary
These changes were followed by gradual symptom relief and long-term disease stabilization, indicating clinical benefit.
2 context sentences(design, population, supporting numbers)
Summary · context
In a young 29-year-old Caucasian woman who was diagnosed with a retromammary desmoid tumor infiltrating deeply into the anterior thoracic wall, surgery was considered excessively mutilating, and observation was recommended.
Summary · context
the patient was instead included in a phase I study investigating transdermal intratumoral injection of LTX-315, an oncolytic peptide that induces anticancer immune responses
Show in the study text Report a problemFND-3117799104
05HumanCase report or seriesSafety outcome
In a woman with a desmoid tumor, LTX‑315 treatment was terminated in week 16 after a serious allergic reaction.
In plain wordsIn a woman with a desmoid tumor, LTX‑315 treatment was stopped in week 16 after a serious allergic reaction.
Peptide
LTX-315
Outcome
Not applicableSerious allergic reaction
Study
n = 1
Outcome group
Adverse events · Cancer
Studied dose
Dose not stated · transdermal intratumoral injectionAs given in this study (human).
Source sentences
Summary
LTX-315 was well tolerated until termination in week 16 after a serious allergic reaction.
2 context sentences(design, population, supporting numbers)
Summary · context
In a young 29-year-old Caucasian woman who was diagnosed with a retromammary desmoid tumor infiltrating deeply into the anterior thoracic wall, surgery was considered excessively mutilating, and observation was recommended.
Summary · context
the patient was instead included in a phase I study investigating transdermal intratumoral injection of LTX-315, an oncolytic peptide that induces anticancer immune responses
Show in the study text Report a problemFND-3117799106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT04796194

Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma

Lytix Biopharma ASn = 235 Nov 2021 to 1 Jul 2025

Advanced Melanoma

Trial page ClinicalTrials.govUpdated 10 Sept 2026

CompletedPhase 1NCT01986426

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

Lytix Biopharma ASn = 80Nov 2013 to 31 Aug 2018

Cancer · Melanoma · Breast Cancer · Head and Neck Cancer · Lymphoma · Triple-Negative Breast Cancer

Trial page ClinicalTrials.govUpdated 3 Oct 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.